Intuitive Surgical reported Q4 2025 results that should reinforce what long-term shareholders already know: this is one of the most durable growth machines in the market.
The company delivered another quarter of solid procedure growth, continued its da Vinci 5 upgrade cycle, and expanded into new clinical frontiers. However, the guidance and management commentary also signalled several headwinds and conservatism that investors need to monitor going into 2026.
Let’s unpack what stood out in this report and conference call.
Financial Results
The Core Engine
The thing that matters most for Intuitive’s long-term thesis is procedure volume growth, and on this front the company continues to deliver. U.S. da Vinci procedures grew 15% in Q4, with strength in after-hours acute care procedures like cholecystectomy and appendectomy, which surged 35%. Outside the U.S., procedures grew an even more +22% YoY.
Global system utilization increased 4%, driven by the efficiency advantages of the new da Vinci 5 platform. This is a key data point that doesn’t get enough attention. But, why?
Higher utilization means the installed base is becoming more productive, which translates directly into recurring revenue growth (instruments, accessories, services). With 81% of Q4 revenue coming from these recurring sources, Intuitive has built a business model that most health-tech companies would kill for.
2026 procedure growth guidance of 13–15% on a base of more than 3.1 million annual procedures highlights the durability of the business. That said, it may have come in a bit light for the Street, especially given tough year-over-year comps and management’s typically conservative posture, familiar to anyone who has followed the name long enough.
Overall, I don’t see a company struggling to sustain growth. Rather, a management team managing expectations while expanding its portfolio of clinical applications.
Da Vinci 5: The Upgrade Cycle Continues
The da Vinci platform continues to be a success. In the US, the company processed 146 trade-in transactions in Q4 versus 62 a year ago. Once again, existing customers view the new system as a meaningful upgrade worth paying for. Surgeon feedback has been positive, and the higher utilization rates confirm that the new da Vinci represents a technological leap forward.
Europe showed a good pace of system placements (118 systems versus 89 last year) and is serving as the primary market for early outside-U.S. da Vinci 5 adoption. The upgrade cycle appears healthy and should continue to drive both system revenue and higher recurring revenue per installed system.
The ASC Strategy: The Positive Surprise for Investors
One of the most interesting developments this quarter was the detail management provided on its multi-year effort to expand into Ambulatory Surgery Centers. The strategy leverages the lower-cost, refurbished da Vinci XIR system and targets higher-volume ASCs, particularly those affiliated with existing hospital customers where surgeons are already trained.
This shows smart capital allocation by management and market segmentation. Intuitive is using a lower-price-point product to address a cost-sensitive setting without cannibalising its premium da Vinci 5 placements.
The ASC market represents a significant untapped opportunity, and the XIR provides a pathway to penetrate it without sacrificing margins on the high end.
Expanding the Clinical Frontier
Intuitive received FDA clearance for several cardiac procedures on da Vinci 5 this quarter. Management emphasised a “measured rollout,” but this officially opens a new, high-acuity market with a TAM estimated at around 160,000 procedures annually.
The company also gained 510(k) clearances for its Single Port system in high-volume procedures including nipple-sparing mastectomy, hernia repair, and cholecystectomy. These clearances should support deeper penetration in 2026, we’ll see.
Management noted that their “line of sight” for addressable procedures has increased from around 7 million in 2024 to approximately 9 million today, driven by strengthening clinical validation in benign procedures and new clearances.
CEO David Rosa framed the company as being in the “early stages of this journey” despite the meaningful progress made. Another indication of the long runway for innovation beyond just procedural penetration.
Headwinds to Monitor
While the core business remains strong, management was transparent about several headwinds facing the company in 2026 in the conference call.
China Competition: Management explicitly called out intensified competition from local players, provincial preferences for domestic suppliers, and pricing pressure that impacted Q4 tender win ratios. This is a key market to monitor. The competitive dynamics in China are deteriorating, and while the company still has advantages, the trajectory here bears watching closely.
Japan Budget Challenges: Persistent government budget constraints continue to pressure capital placements in Japan. This has been an ongoing issue and doesn’t appear to be resolving quickly.
Margin Pressure: The impact of tariffs on gross margin is expected to nearly double in 2026 to 120 basis points of revenue (up from around 70 basis points in 2025). Management’s 2026 gross margin guidance of 67-68% is effectively flat YoY, as cost reduction efforts are being offset by tariff headwinds and product mix.
U.S. Healthcare Policy Uncertainty: Management noted potential impacts from changes to U.S. healthcare subsidies (ACA/Medicaid) as a risk factor. This is a newly articulated concern that could impact hospital finances and, consequently, patient procedure volumes.
Europe Macro Concerns: Broader macroeconomic pressures and capital budget constraints in Europe (particularly the UK) could continue to weigh on system placements.
What This Means for Valuation and Long-Term Returns
In my view, Intuitive remains one of the highest-quality compounding machines in the Healthcare technology industry. The business has a dominant market position, a widening technological moat, expanding clinical applications, and a highly predictable recurring revenue model. These are not things that change overnight.
That said, investors need to be realistic about what they’re underwriting. The 13–15% procedure growth guidance for 2026 is solid and steady, but it does represent a modest deceleration from historical levels, all while the stock trades at roughly 43x forward EV/EBITDA.
Operating expense growth of 11–15%, driven by higher R&D spending and distributor acquisitions, combined with largely flat gross margins, suggests operating leverage will be more muted than in prior periods.
As always with ISRG, it remains to be seen whether this outlook reflects normalization or the management team’s familiar conservatism in setting expectations.
The thing is that even under these conservative assumptions, Intuitive’s competitive position continues to strengthen. The da Vinci 5 extends its technological lead. The XIR system enables better market segmentation to address more cost-sensitive settings. Expansion into cardiac surgery and new Single Port indications reinforces the platform’s clinical utility.
With recurring revenue now accounting for ~81% of total sales, the business offers incredible quality and predictability. This is high-quality compounding at its finest.
What to Watch in 2026
For those of us monitoring Intuitive closely, here are the key questions to focus on:
Cardiac and Single Port rollout pace: How quickly do these new indications contribute to procedure growth? Early traction here would be a positive signal.
XIR system adoption in ASCs: What are the placement volumes and utilization rates? This could be a meaningful growth driver if executed well.
China competitive dynamics: Are tender win-rates stabilizing or continuing to deteriorate outside the US? This will tell us whether the competitive pressure is transitory or structural.
MyIntuitive Plus monetization: Beginning mid-year, the digital subscription package becomes a paid offering for renewing customers. The renewal rate and pricing will be important indicators of value delivery and pricing power.
Margin trajectory: Can the company offset tariff headwinds through operational efficiency, or will margins face continued pressure?
Thanks for following along,
—Nikotes
Unlock Premium Content – For just $0.39/day ($12/month) or $0.27/day ($100/year)!
🔗 Portfolio Corner - 🗓️ Monthly Updates (Last Update: 26-Dec-2025)
